osteoarthritis

Are non-opioid therapies more desirable than opioids for chronic pain?A new study from researchers from the Minneapolis VA Health Care System has interesting findings.
New osteoarthritis drug expands options for low-dose NSAIDsFDA approved meloxicam (Vivlodex, Iroko Pharmaceuticals, LLC) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain in 5-mg and 10-mg doses administered once daily.
Study questions use of paracetamol for lower back pain and osteoarthritisParacetamol is ineffective in reducing pain, disability or improving quality of life for patients who suffer from low back pain or osteoarthritis of the hip or knee, and its use may affect the liver, according to a study published BMJ.
Most medications found better than Tylenol for knee painMost treatments for pain caused by knee osteoarthritis helped alleviate pain better than acetaminophen (Tylenol) – with one exception, according to a study published in the January 6 issue of the Annals of Internal Medicine
FDA approves diclofenac for managing OA painZorvolex was the first FDA-approved low dose NSAID developed using proprietary SoluMatrix Fine Particle Technology. Zorvolex contains diclofenac as submicron particles that are approximately 20 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution. By using this technology, the dose can be lowered without delaying absorbtion.
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval
Investigational drug in phase 3 study has potential to be first DMARD for knee osteoarthritisWith global disability concerns rising, Voltarra Pharmaceuticals, Inc. and Menzies Research Institute at the University of Tasmania in Hobart, Australia, have initiated a phase 3, randomized multicenter clinical trial to assess the efficacy and safety of VOLT01 for controlling knee osteoarthritis (OA).
OARSI provides guidance on non-surgical management of knee osteoarthritisOsteoarthritis of the knee is a major cause of pain and disability affecting a growing number of patients due to population aging. Here are the recently released guidelines from the Osteoarthritis Research Society International (OARSI), which provide recommendations on the use of available non-surgical therapies.
FDA drug approvals: March 2014FDA actions in brief, breakthrough therapy designations, priority review, fast-track designations, orphan drug designations
OA treatment for knee pain approved by FDAFDA has approved hyaluronic acid (HA) injection (Monovisc, Anika Therapeutics), a single-injection supplement to synovial fluid of the osteoarthritic joint, for the treatment of pain and the improvement of joint mobility in patients with osteoarthritis (OA) of the knee.